Merlin is closely related to ezrin, radixin and moesin (ERMs) — membrane–cytoskeleton-associated proteins that belong to the protein 4.1 superfamily. Although merlin is the only member of the merlin/ERM subfamily that is known to function as a tumour suppressor, common subcellular localization, shared interacting partners and physical interaction between merlin and the ERMs indicate that functional overlap exists. Mouse models indicate that merlin inactivation might have an unappreciated role in human cancer aetiology. So, could the ERM proteins also have a role in cancer development?
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Baser, M. E., Evans, D. G. & Gutmann, D. H. Neurofibromatosis 2. Curr. Opin. Neurol. 16, 27–33 (2003).
Trofatter, J. A. et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the Neurofibromatosis 2 tumor suppressor. Cell 72, 791–800 (1993).
Rouleau, G. A. et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363, 515–521 (1993).
McClatchey, A. I., Saotome, I., Ramesh, V., Gusella, J. F. & Jacks, T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 11, 1253–1265 (1997).
McClatchey, A. I. et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 12, 1121–1133 (1998).
Giovannini, M. et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 14, 1617–1630 (2000).
Kalamarides, M. et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes Dev. 16, 1060–1065 (2002).
Doi, Y. et al. Normal development of mice and unimpaired cell adhesion/cell motility/actin-based cytoskeleton without compensatory up-regulation of ezrin or radixin in moesin gene knockout. J. Biol. Chem. 274, 2315–2321 (1999).
Kikuchi, S. et al. Radixin deficiency causes conjugated hyperbilirubinemia with loss of Mrp2 from bile canalicular membranes. Nature Genet. 31, 320–325 (2002).
Bretscher, A., Edwards, K. & Fehon, R. G. ERM proteins and merlin: integrators at the cell cortex. Nature Rev. Mol. Cell Biol. 3, 586–599 (2002).
Tran Quang, C., Gautreau, A., Arpin, M. & Treisman, R. Ezrin function is required for ROCK-mediated fibroblast transformation by the Net and Dbl oncogenes. EMBO J. 19, 4565–4576 (2000).
Crepaldi, T., Gautreau, A., Comoglio, P., Louvard, D. & Arpin, M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138, 423–434 (1997).
Wick, W. et al. Ezrin-dependent promotion of glioma cell clonogenecity, motility, and invasion mediated by BCL-2 and transforming growth factor-β2. J. Neurosci. 21, 3360–3368 (2001).
Akisawa, N., Nishimori, I., Iwamura, T., Onishi, S. & Hollingsworth, M. A. High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem. Biophys. Res. Commun. 258, 395–400 (1999).
Nestl, A. et al. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Canc. Res. 61, 1569–1577 (2001).
Khanna, C. et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Canc. Res. 61, 3750–3759 (2001).
McCartney, B. M. & Fehon, R. G. Distinct cellular and subcellular patterns of expression imply distinct functions for the Drosophila homologues of moesin and the Neurofibromatosis 2 tumor suppressor, merlin. J. Cell Biol. 133, 843–852 (1996).
Boedigheimer, M. & Laughon, A. Expanded: a gene involved in the control of cell proliferation in imaginal discs. Development 118, 1291–1301 (1993).
Tran, Y. K. et al. A novel member of the NF2/ERM/4.1 superfamily with growth suppressing properties in lung cancer. Cancer Res. 59, 35–43 (1999).
Chishti, A. et al. The FERM domain: a unique module involved in the linkage of cytoplasmic proteins to the membrane. Trends Biochem. Sci. 23, 281–282 (1998).
James, M. F., Manchanda, N., Gonzalez-Agosti, C., Hartwig, J. H. & Ramesh, V. The Neurofibromatosis 2 protein product merlin selectively binds F-actin but not G-actin, and stabilizes the filaments through a lateral association. Biochem. J. 356, 377–386 (2001).
Scoles, D. R. et al. Neurofibromatosis 2 tumour suppressor schwannomin interacts with βII-spectrin. Nature Genet. 18, 354–359 (1998).
Berryman, M., Gary, R. & Bretscher, A. Ezrin oligomers are major cytoskeletal components of placental microvilli: a proposal for their involvement in cortical morphogenesis. J. Cell Biol. 131, 1231–1242 (1995).
Gautreau, A., Louvard, D. & Arpin, M. Morphogenic effects of ezrin require a phosphorylation-induced transition from oligomers to monomers at the plasma membrane. J. Cell Biol. 150, 193–203 (2000).
Pearson, M. A., Reczek, D., Bretscher, A. & Karplus, P. A. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 101, 259–270 (2000).
Nakamura, F., Amieva, M. R. & Furthmayr, H. Phosphorylation of threonine 558 in the carboxyl-terminal actin-binding domain of moesin by thrombin activation of human platelets. J. Biol. Chem. 270, 31377–31385 (1995).
Matsui, T. et al. Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J. Cell Biol. 140, 647–657 (1998).
Bretscher, A. Rapid phosphorylation and reorganization of ezrin and spectrin accompany morphological changes induced in A-431 cells by epidermal growth factor. J. Cell Biol, 108, 921–930 (1989).
Krieg, J. & Hunter, T. Identification of the two major epidermal growth factor-induced tyrosine phosphorylation sites in the microvillar core protein ezrin. J. Biol. Chem. 267, 19258–19265 (1992).
Berryman, M., Franck, Z. & Bretscher, A. Ezrin is concentrated in the apical microvilli of a wide variety of epithelial cells whereas moesin is found primarily in endothelial cells. J. Cell Sci. 105, 1025–1043 (1993).
Yang, H. -S. & Hinds, P. W. Increased ezrin expression and activation by cdk5 coincident with acquisition of the senescent phenotype. Mol. Cell 11, 1163–1176 (2003).
Niggli, V., Andreoli, C., Roy, C. & Mangeat, P. Identification of a phosphatidylinositol-4,5-bisphosphate-binding domain in the N-terminal region of ezrin. FEBS Lett. 376, 172–176 (1995).
Yonemura, S., Matsui, T., Tsukita, S. & Tsukita, S. Rho-dependent and -independent activation mechanisms of ezrin/radixin/moesin proteins: an essential role for polyphosphoinositides in vivo. J. Cell Sci. 115, 2569–2580 (2002).
Shaw, R. J., McClatchey, A. I. & Jacks, T. Regulation of the neurofibromatosis type 2 tumor suppressor protein, merlin, by adhesion and growth arrest stimuli. J. Biol. Chem. 273, 7757–7764 (1998).
Shaw, R. J. et al. The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling. Dev. Cell. 1, 63–72 (2001).
LaJeunesse, D. R., McCartney, B. M. & Fehon, R. G. Structural analysis of Drosophila merlin reveals functional domains important for growth control and subcellular localization. J. Cell Biol. 141, 1589–1599 (1998).
Gonzalez-Agosti, C., Wiederhold, T., Herndon, M. E., Gusella, J. F. & Ramesh, V. Interdomain interaction of merlin isoforms and its influence on intermolecular binding to NHE-RF. J. Biol. Chem. 274, 34438–34442 (1999).
Gronholm, M. et al. Homotypic and heterotypic interaction of the Neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein. J. Cell Sci. 112, 895–904 (1999).
Meng, J. J. et al. Interaction between two isoforms of the NF2 tumor suppressor protein, merlin, and between merlin and ezrin, suggesting modulation of ERM proteins by merlin. J. Neurosci. Res. 62, 491–502 (2000).
Nguyen, R., Reczek, D. & Bretscher, A. Hierarchy of merlin and ezrin N- and C-terminal domain interactions in homo- and heterotypic associations and their relationship to binding of scaffolding proteins EBP50 and E3KARP. J. Biol. Chem. 276, 7621–7629 (2001).
Etienne-Manneville, S. & Hall, A. Rho GTPases in cell biology. Nature 420, 629–635 (2002).
Shaw, R. J., Henry, M., Solomon, F. & Jacks, T. RhoA-dependent phosphorylation and relocalization of ERM proteins into apical membrane/actin protrusions in fibroblasts. Mol. Biol. Cell 9, 403–419 (1998).
Kissil, J. L., Johnson, K. C., Eckman, M. S. & Jacks, T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization. J. Biol. Chem. 277, 10394–10399 (2002).
Xiao, G. H., Beeser, A., Chernoff, J. & Testa, J. R. p21-activated kinase links Rac/cdc42 signaling to merlin. J. Biol. Chem. 277, 883–886 (2002).
Speck, O., Hughes, S. C., Noren, N. K., Kulikauskas, R. M. & Fehon, R. G. Moesin functions antagonistically to the Rho pathway to maintain epithelial integrity. Nature 421, 83–87 (2003).
Lamb, R. F. et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nature Cell Biol. 2, 281–287 (2000).
Mackay, D. J., Esch, F., Furthmayr, H. & Hall, A. Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J. Cell Biol. 138, 927–938 (1997).
Takahashi, K. et al. Interaction of radixin with Rho small G protein GDP/GTP exchange protein, Dbl. Oncogene 16, 3279–3284 (1998).
Takahashi, K. et al. Direct interaction of the Rho GDP dissociation inhibitor with ezrin/radixin/moesin initiates the activation of the Rho small G protein. J. Biol. Chem. 272, 23371–23375 (1997).
Maeda, M., Matsui, T., Imamura, M., Tsukita, S. & Tsukita, S. Expression level, subcellular distribution and rho-GDI binding affinity of merlin in comparison with ezrin/radixin/moesin proteins. Oncogene 18, 4788–4797 (1999).
Sahai, E. & Marshall, C. RHO-GTPases and cancer. Nature Rev. Cancer 2, 133–142 (2002).
LaJeunesse, D. R., McCartney, B. M. & Fehon, R. G. A systematic screen for dominant second-site modifiers of merlin/NF2 phenotypes reveals an interaction with blistered/DSRF and scribbler. Genetics, 158, 667–679 (2001).
DeClue, J. E. et al. Epidermal growth factor receptor expression in Neurofibromatosis type 1-related tumors and NF1 animal models. J. Clin. Invest. 105, 1233–1124 (2000).
Scoles, D. R. et al. The Neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum. Mol. Genet. 9, 1567–1574 (2000).
Stahl, P. D. & Barbieri, M. Multivesicular bodies and multivesicular endosomes: the “ins” and “outs” of endosomal traffic. Sciences STKE [online], (cited 16 Jul. 2002), <http://stke.sciencemag.org/cgi/content/full/OC_sigtrans;2002/141/pe32> (2002).
Reczek, D., Berryman, M. & Bretscher, A. Identification of EBP50: a PDZ-containing phosphoprotein that associates with members of the ezrin-radixin-moesin family. J. Cell Biol. 139, 169–179 (1997).
Murthy, A. et al. NHE-RF, a regulatory factor for Na(+)-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins. J. Biol. Chem. 273, 1273–1276 (1998).
Maudsley, S. et al. Platelet-derived growth factor receptor association with Na(+)/H(+) exchanger regulatory factor potentiates receptor activity. Mol. Cell Biol. 20, 8352–8363 (2000).
Reczek, D. & Bretscher, A. Identification of EPI64, a TBC/rabGAP domain-containing microvillar protein that binds to the first PDZ domain of EBP50 and E3KARP. J. Cell Biol. 153, 191–206 (2001).
Tsukita, S. et al. ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeleton. J. Cell Biol. 126, 391–401 (1994).
Sainio, M. et al. Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton. J. Cell Sci. 110, 2249–2260 (1997).
Morrison, H. et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 15, 968–980 (2001).
Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074–3086 (2002).
Bourguignon, L. Y. et al. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J. Biol. Chem. 272, 27913–27918 (1997).
Sherman, L. S., Rizvi, T. A., Karyala, S. & Ratner, N. CD44 enhances neuregulin signaling by Schwann cells. J. Cell Biol. 150, 1071–1084 (2000).
Fernandez-Valle, C. et al. Paxillin binds schwannomin and regulates its density-dependent localization and effect on cell morphology. Nature Genet. 31, 354–362 (2002).
Lallemand, D., Curto, M., Saotome, I., Giovannini, M. & McClatchey, A. I. NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. Genes Dev. 17, 1090–1100 (2003).
Pujuguet, P., Del Maestro, L., Gautreau, A., Louvard, D. & Arpin, M. Ezrin regulates E-cadherin-dependent adherens junction assembly through Rac1 activation. Mol. Biol. Cell 14, 2181–2191 (2003).
Nollet, F., Berx, G. & van Roy, F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol. Cell. Biol. Res. Comm. 2, 77–85 (2000).
Grazia Lampugnani, M. et al. Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J. Cell Biol. 161, 793–804 (2003).
Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442–454 (2002).
Vermeer, P. D. et al. Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 422, 322–326 (2003).
Gautreau, A. et al. Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J. Biol. Chem. 277, 31279–31282 (2002).
Kimura, Y. et al. The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nature Med. 4, 915–922 (1998).
Korf, B. R. Clinical features and pathobiology of NF1. J. Child Neurol. 17, 573–577 (2002).
Lee, W. C. & Testa, J. R. Somatic alterations in human malignant mesothelioma. Int. J. Oncol. 14, 181–188 (1999).
Melendez-Vasquez, C. V. et al. Nodes of Ranvier form in association with ezrin-radixin-moesin (ERM)-positive Schwann cell processes. Proc. Natl Acad. Sci USA 98, 1235–1240 (2001).
Scherer, S. S., Xu, T., Crino, P., Arroyo, E. J. & Gutmann, D. H. Ezrin, radixin, and moesin are components of Schwann cell microvilli. J. Neurosci Res. 65, 150–164 (2001).
Cullinan, P., Sperling, A. I. & Burkhardt, J. K. The distal pole complex: a novel membrane domain distal to the immunological synapse. Immunol. Rev. 189, 111–122 (2002).
Miller, K. G. A role for moesin in polarity. Trends Cell Biol. 13, 165–168 (2003).
Takeda, T., McQuistan, T., Orlando, R. A. & Farquhar, M. G. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J. Clin. Invest. 108, 289–301 (2001).
Denisenko-Nehrbass, N. et al. Association of Caspr/paranodin with tumour suppressor schwannomin/merlin and β1 integrin in the central nervous system. J. Neurochem. 84, 209–221
Sherman, L. et al. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 15, 2505–2509 (1997).
Johnson, K. C., Kissil, J. L., Fry, J. L. & Jacks, T. Cellular transformation by a FERM domain mutant of the Nf2-tumor suppressor gene. Oncogene 21, 5990–5997 (2002).
Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978–986 (1999).
It was very difficult to keep the scope of this review focused given the amount of interesting work that has been published recently — I apologize to those whose work was omitted or only briefly mentioned due to space limitations. I would like to thank M. Curto and D. Lallemand for their comments and interesting speculative discussions. A. I. M. is supported by the American Cancer Society and the Department of Defense.
About this article
Cite this article
McClatchey, A. Merlin and ERM proteins: unappreciated roles in cancer development?. Nat Rev Cancer 3, 877–883 (2003). https://doi.org/10.1038/nrc1213
Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer
International Journal of Pharmaceutics (2021)
PFOS ile tedavi edilen Sertoli hücre kültüründe ezrin ve fascin 1'in değerlendirilmesi: İn vitro bir çalışma
Acta Medica Alanya (2020)
Frontiers in Cell and Developmental Biology (2020)
Characterization of the Frmd7 Knock-Out Mice Generated by the EUCOMM/COMP Repository as a Model for Idiopathic Infantile Nystagmus (IIN)
Cancer Science (2020)